HCV Competition Not New “News” for Gilead
publication date: Dec 25, 2014
Gilead is trading more than 40% above its 52-week low and about 20% from its 52-week high. We see no reason to panic, and the company’s trading activity more closely reflects a company whose stock price has quintupled in recent years than one that is in any trouble whatsoever. Gilead’s shares bounced right off technical support levels, and we see a long term that is still very bright for the biotech. Gilead’s shares remain underpriced even under a bear-case scenario.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.